Brief: Actinium Pharmaceuticals And Aveo Oncology Enter Research Collaboration Agreement
Feb 22 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. AND AVEO ONCOLOGY ENTER
RESEARCH
COLLABORATION AGREEMENT TO DEVELOP FIRST-IN-CLASS ACTINIUM-225
ERBB3 TARGETING RADIOTHERAPY FOR SOLID TUMORS
Source text for Eikon: ID:nPn2xzFKFa
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities